Chronic viral hepatitis as a public health issue in the world

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 6, 2008, Pages 991-1008

  Lavanchy, Daniel ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

cirrhosis; epidemiology; HBV; HCC; HCV; hepatitis B; hepatitis C; liver cancer; prevention; vaccination

Indexed keywords

ANTIVIRUS AGENT; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ACUPUNCTURE; ARTICLE; BLOOD TRANSFUSION; BODY PIERCING; CIRCUMCISION; DISEASE SURVEILLANCE; DISINFECTION; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFORMATION DISSEMINATION; INSTRUMENT STERILIZATION; INTRAVENOUS DRUG ABUSE; LIVER CANCER; LIVER CIRRHOSIS; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; OCCUPATIONAL EXPOSURE; PASSIVE IMMUNIZATION; PERSONAL HYGIENE; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RISK REDUCTION; SAFE SEX; SCAR FORMATION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SHARPS DISPOSAL; TATTOOING; TRAVEL; VERTICAL TRANSMISSION; VIRAL CONTAMINATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DISEASE TRANSMISSION, INFECTIOUS; HEALTH POLICY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; PREVENTIVE HEALTH SERVICES; PUBLIC HEALTH PRACTICE; WORLD HEALTH;

EID: 58949093626     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.11.002     Document Type: Article

References (99)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
2. Mahoney F.J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12 (1999) 351-366
3. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
4. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
5. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 74 (1999) 425-427
6. Alter M.J. Epidemiology of hepatitis C. Hepatology 26 (1997) 62S-65S
7. Dore G.J., Freeman A.J., Law M., et al. Is severe liver disease a common outcome for people with chronic hepatitis C?. J Gastroenterol Hepatol 17 (2002) 423-430
8. Verbaan H., Hoffmann G., Lindgren S., et al. Long-term outcome of chronic hepatitis C infection in a low-prevalence area. Scand J Gastroenterol 33 (1998) 650-655
9. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44 (2004) 20-29
10. McMahon B.J., Holck P., Bulkow L., et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135 (2001) 759-768
11. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
12. Pokorski R.J., and Ohlmer U. Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus. J Insur Med 33 (2001) 143-164
13. Lemon S.M., Layden T.J., Seeff L., et al. The 20th United States-Japan joint hepatitis panel meeting. Hepatology 31 (2000) 800-806
14. Stroffolini T., Andreone P., Andriulli A., et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29 (1998) 944-952
15. Kuper H.E., Tzonou A., Kaklamani E., et al. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control 11 (2000) 171-175
16. Brechot C., Jaffredo F., Lagorce D., et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 29 (1998) 173-183
17. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21 (1995) 77-82
18. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
19. Francis D.P., Favero M.S., and Maynard J.E. Transmission of hepatitis B virus. Semin Liver Dis 1 (1981) 27-32
20. Gust I.D. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38 Suppl 2 (1996) S18-S23
21. Chen C.J., Wang L.Y., and Yu M.W. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 15 Suppl (2000) E3-E6
22. Schmunis G.A., Zicker F., Cruz J.R., et al. Safety of blood supply for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg 65 (2001) 924-930
23. WHO Global Database on Blood Safety. Report 2001-2002; 2004.
24. Simonsen L., Kane A., Lloyd J., et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77 (1999) 789-800
25. Kane A., Lloyd J., Zaffran M., et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 77 (1999) 801-807
26. Hutin Y.J., and Chen R.T. Injection safety: a global challenge. Bull World Health Organ 77 (1999) 787-788
27. Hutin Y.J., Harpaz R., Drobeniuc J., et al. Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. Int J Epidemiol 28 (1999) 782-786
28. Hadler S.C., Doto I.L., Maynard J.E., et al. Occupational risk of hepatitis B infection in hospital workers. Infect Control 6 (1985) 24-31
29. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 75 (2000) 18-19
30. Hepatitis C: global prevalence. Wkly Epidemiol Rec 72 (1997) 341-344
31. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6 (1999) 35-47
32. Wasley A., and Alter M. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
33. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 (1997) 15S-20S
34. Kew M. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Viral Hepat Rev 4 (1998) 259-269
35. Donahue J.G., Munoz A., Ness P.M., et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327 (1992) 369-373
36. Garfein R.S., Vlahov D., Galai N., et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 86 (1996) 655-661
37. Meky F.A., Stoszek S.K., Abdel-Hamid M., et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis 42 (2006) 628-633
38. Medhat A., Shehata M., Magder L.S., et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 66 (2002) 633-638
39. Stoszek S.K., Abdel-Hamid M., Narooz S., et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 100 (2006) 102-107
40. Hagan H., McGough J.P., Thiede H., et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 149 (1999) 203-213
41. Hilleman M.R., Buynak E.B., Roehm R.R., et al. Purified and inactivated human hepatitis B vaccine. Am J Med Sci 270 (1976) 401-404
42. Andre F.E., and Safary A. Clinical experience with a yeast derived hepatitis B vaccine. In: Zuckerman A.J. (Ed). Viral Hepatitis and Liver Disease (1988), Alan R. Liss, New York
43. Lavanchy D. Hepatitis B vaccines and immunization. In: Rhodes J., Benhamou J.-P., and Blei A. (Eds). Textbook in Hepatology vol. 1 (2007), Blackwell 907-916
44. Harpaz R., McMahon B.J., Margolis H.S., et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 181 (2000) 413-418
45. FitzSimons D., Francois G., Hall A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23 (2005) 4158-4166
46. Zanetti A.R., Mariano A., Romano L., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 (2005) 1379-1384
47. Zoulim F. Hepatitis C virus infection in special groups. J Hepatol 31 (1999) 130-135
48. Yang Y.J., Liu C.C., Chen T.J., et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 22 (2003) 584-588
49. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 (1995) S47-S49
50. Grosheide P., and van Damme P. Prevention and control of hepatitis B in the community. Commun Dis Series 1 (1996) 1-60
51. Bonanni P., and Bonaccorsi G. Vaccination against hepatitis B in health care workers. Vaccine 19 (2001) 2389-2394
52. Roggendorf M., and Viazov S. Health care workers and hepatitis B. J Hepatol 39 (2003) S89-S92
53. Stevens C.E., Alter H.J., Taylor P.E., et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311 (1984) 496-501
54. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. N Engl J Med 334 (1996) 1685-1690
55. Alter M.J. Epidemiology and prevention of hepatitis B. Semin Liver Dis 23 (2003) 39-46
56. Mast E.E., Alter M.J., and Margolis H.S. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 17 (1999) 1730-1733
57. Chen H.L., Chang M.H., Ni Y.H., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276 (1996) 906-908
58. Tsebe K.V., Burnett R.J., Hlungwani N.P., et al. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 19 (2001) 3919-3926
59. Burke J. Breastfeeding. Am J Nurs 105 (2005) 15
60. Recommendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Morb Mortal Wkly Rep 40 (1991) 1-19
61. Gerbase A.C., Rowley J.T., Heymann D.H., et al. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 74 (1998) S12-S16
62. Alter M.J., Hadler S.C., Margolis H.S., et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 263 (1990) 1218-1222
63. Bock H.L., Loscher T., Scheiermann N., et al. Accelerated Schedule for Hepatitis B Immunization. J Travel Med 2 (1995) 213-217
64. Butler T.G., Dolan K.A., Ferson M.J., et al. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust 166 (1997) 127-130
65. Spaulding A.C., Lally M., Rich J.D., et al. Hepatitis B and C in the context of HIV disease: implications for incarcerated populations. AIDS Read 9 (1999) 481-491
66. Scientific Advisory Group of Experts (SAGE). Hepatitis B control through immunization. In: WHO Global Programme for Vaccines and Immunization, GPV/SAGE.96/WP.02; 1996.
67. Prince A.M. Control of hepatitis B virus infection in Third-World countries. Transfus Med Rev 4 (1990) 187-190
68. Zanetti A.R., Tanzi E., Romano L., et al. Vaccination against hepatitis B: the Italian strategy. Vaccine 11 (1993) 521-524
69. Zuckerman A.J. Hepatitis viruses. In: Baron S. (Ed). Medical Microbiology. 4 ed. (1996), The University of Texas Medical Branch at Galveston, Galveston 849-863
70. Ni Y.H., Chang M.H., Huang L.M., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 135 (2001) 796-800
71. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
72. Stroffolini T., Mele A., Tosti M.E., et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 33 (2000) 980-985
73. Gatcheva N., Vladimirova N., and Kourtchatova A. Implementing universal vaccination programmes: Bulgaria. Vaccine 13 Suppl 1 (1995) S82-S83
74. Bonanni P. Universal hepatitis B immunization: infant, and infant plus adolescent immunization. Vaccine 16 (1998) S17-S22
75. Tepper M.L. Universal hepatitis B immunization: young adolescent immunization. Vaccine 16 (1998) S23-S26
76. VHPB (Viral Hepatitis Prevention Board). Combined hepatitis B vaccines. J Viral Hepat 10 (2002) 1-20
77. Henderson D.A. Lessons from the eradication campaigns. Vaccine 17 Suppl. 3 (1999) 53-55
78. Bonanni P., Colombai R., Gasparini R., et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 18 (1999) 677-682
79. Chauveau P. Epidemiology of hepatitis C virus infection in chronic haemodialysis. Nephrol Dial Transplant 11 Suppl 4 (1996) 39-41
80. Wreghitt T.G. Bloodborne virus infections in dialysis units: a mini-review. Commun Dis Public Health 7 (2004) 92-93
81. Natov S.N., and Pereira B.J. Hepatitis C in dialysis patients. Adv Ren Replace Ther 3 (1996) 275-283
82. Bukh J., Wantzin P., Krogsgaard K., et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 168 (1993) 1343-1348
83. Natov S.N. Hepatitis C virus in chronic dialysis patients. Minerva Urol Nefrol 57 (2005) 175-197
84. Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant 11 Suppl 4 (1996) 36-38
85. Keeffe E.B. Update on liver transplantation. Rev Gastroenterol Mex 69 Suppl 3 (2004) 160-170
86. Mele A., Spada E., Sagliocca L., et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol 35 (2001) 284-289
87. Krause G., Trepka M.J., Whisenhunt R.S., et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol 24 (2003) 122-127
88. Sanchez-Tapias J.M. Nosocomial transmission of hepatitis C virus. J Hepatol 31 Suppl 1 (1999) 107-112
89. Subbarao I., Steinbrecher R., Tan L., et al. Postexposure immunization and prophylaxis of bloodborne pathogens following a traumatic explosive event: preliminary recommendations. Disaster Med Public Health Prep 1 (2007) 106-109
90. FitzSimons D., François G., De Carli G., et al. Hepatitis B, hepatitis C, and other blood-borne infections in healthcare workers: guidelines for prevention and management. Occup Environ Med 65 (2008) 446-451
91. Roy K., Hay G., Andragetti R., et al. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 129 (2002) 577-585
92. Somaini B., Wang J., Perozo M., et al. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care 12 (2000) 449-460
93. Sarkar K., Mitra S., Bal B., et al. Rapid spread of hepatitis C and needle exchange programme in Kolkata, India. Lancet 361 (2003) 1301-1302
94. Dolan K., Rutter S., and Wodak A.D. Prison-based syringe exchange programmes: a review of international research and development. Addiction 98 (2003) 153-158
95. Spaulding A.C., Weinbaum C.M., Lau D.T.-Y., et al. A framework for management of hepatitis C in prisons. Ann Intern Med 144 (2006) 762-769
96. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
97. Management of occupational blood exposures. J Am Dent Assoc 133 (2002) 1630
98. Margolis H.S., Coleman P.J., Brown R.E., et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274 (1995) 1201-1208
99. Rosenberg D., Cook S., Eaton S., et al. The epidemiology, treatment patterns and resource utilization of hepatitis B patients in a large insured New England population. Pharmcoepidmiol Drug Saf 7 (1998) S132